ChitogenX, Inc. is a clinical stage biotech company, which engages in the development of therapeutic soft tissue repair technologies for orthopaedic and sports medicine surgeries. The company is headquartered in Kirkland, Quebec. The company went IPO on 2017-10-10. The firm is engaged in the development of therapeutic tissue repair technologies to improve tissue healing. The firm is committed to the clinical development of its proprietary RESTORE technology platform, a muco-adhesive CHITOSAN based biopolymer matrix, specifically designed to deliver biologics such as platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC), to enhance healing in various musculoskeletal conditions. Ortho-R, its lead Chitosan-PRP hybrid biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports related injuries to tendons, ligaments, and cartilage such as the meniscus. Its other formulations are being developed to leverage the technology's performance characteristics, such as tissue adhesion, pliability, and ability to deliver biologics or therapeutics to various tissues damaged by trauma or disease.
Follow-Up Questions
CHNXF 주식의 가격 성능은 어떻습니까?
CHNXF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Chitogenx Inc의 주요 사업 주제나 업종은 무엇입니까?
Chitogenx Inc은 N/A 업종에 속하며, 해당 부문은 N/A입니다
Chitogenx Inc의 시가총액은 얼마입니까?
Chitogenx Inc의 현재 시가총액은 $0입니다
Chitogenx Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Chitogenx Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
